Depression scores reduced significantly for single 25-mg dose versus 1-mg dose, but not for single 10-mg dose
THURSDAY, Nov. 3, 2022 (HealthDay News) — A single 25-mg dose of psilocybin reduces depression scores significantly more than a 1-mg dose over a three-week period among individuals with treatment-resistant depression, according to a study published in the Nov. 3 issue of the New England Journal of Medicine.
Guy M. Goodwin, from King’s College London, and colleagues conducted a phase 2 double-blind trial involving adults with treatment-resistant depression randomly assigned to receive a single dose of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control) with psychological support (79, 75, and 79 participants, respectively).
The researchers found that the mean Montgomery-Åsberg Depression Rating Scale total score was 32 or 33 in each group at baseline. The least-squares mean change from baseline to week 3 was −12.0, −7.9, and −5.4 for 25, 10, and 1 mg, respectively; the difference between the 25- and 1-mg groups was −6.6 (95 percent confidence interval, −10.2 to −2.9; P
“Longer and larger trials, including comparison with existing treatments for depression, are required to determine the efficacy and safety of psilocybin for treatment-resistant depression,” the authors write.
Editorial (subscription or payment may be required)
Copyright © 2022 HealthDay. All rights reserved.